Daewoong Pharmaceutical Q3 Operating Profit 37.3 Billion KRW... 27% Increase YoY
Daewoong Pharmaceutical announced on the 30th that its consolidated operating profit for the third quarter of this year was tentatively estimated at 37.3 billion KRW, a 27% increase compared to the same period last year. Sales reached 358.4 billion KRW, up 5% during the same period. Net profit was 28.4 billion KRW.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Iranian Military Spokesperson: "Ceasefire Was an Opportunity to Strengthen Forces... Ready to Respond to War"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Daewoong Pharmaceutical explained that the improved performance was driven by strong sales of key products such as the gastroesophageal reflux disease treatment 'Pexuclu' and the botulinum toxin 'Nabota'.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
